Kura Oncology and Kyowa Kirin announced that clinical data from the KOMET-007 trial, evaluating ziftomenib in combination with the standard chemotherapy regimen of cytarabine and daunorubicin (7+3) ...
Revumenib demonstrates significant efficacy in R/R AML with NPM1m, KMT2Ar, and NUP98r, showing high response rates and tolerability. The AUGMENT-101 study reports a 26% CR/CRh rate in NPM1-mutated AML ...
Allo-HSCT significantly improved survival in real-world pediatric AML, with CR1 patients showing the best outcomes, achieving OS and DFS rates of 84.2% and 73.4%. Matched sibling and unrelated donors ...
PRESS RELEASEAB SCIENCE REPORTS FOURTH CONSECUTIVE CASE OF RESPONSE FROM PHASE 1 DATA FOR THE COMBINATION OF AB8939 WITH VENETOCLAX FOR THE ...
Acute myeloid leukemia (AML) is a type of blood and bone marrow cancer. AML can affect people of any age, but it is most common in adults. AML occurs when bone marrow produces abnormal blood cells, ...
A DNA aptamer nanostructure enables targeted doxorubicin delivery to AML cells, improving treatment efficacy and safety, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback